We consider new imaging approaches showing sensitivity to brain tissue composition, and examine novel fluid biomarkers showing specificity for pathological...
3 months ago

Dementia is an umbrella term—caused by a large number of specific diagnoses, including several neurodegenerative disorders. Alzheimer's disease (AD) is now...
8 months ago

Diagnosis of dementia with Lewy bodies (DLB) is challenging, largely due to a lack of diagnostic tools. Cerebrospinal fluid (CSF) biomarkers...
51 months ago

Diagnosis of dementia with Lewy bodies (DLB) is challenging and specific biofluid biomarkers are highly needed.
12 months ago

Alzheimer's disease (AD) is the most common form of dementia affecting 60%–70% of people afflicted with this disease.
39 months ago

Providing an accurate prognosis for individual dementia patients remains a challenge since they greatly differ in rates of cognitive decline...
17 months ago

Studies within the last few decades provide growing evidence for a central role of amyloid β (Aβ) and tau, as well as glial contributions to various molecular...
50 months ago

Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease (AD), and its accumulation has been considered as...
15 months ago

Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the center of Alzheimer's disease (AD) pathophysiology.
37 months ago

In this review, we consider the capabilities and limitations of fluid biomarkers collected from cerebrospinal fluid, blood, and oral, ocular, and olfactory...
65 months ago